Replimune Q4 net loss $74.1M; RP1 BLA on track for July 22 PDUFA

Replimune Group, Inc.

2025-FY EPS reported -$3.07 vs consensus -$0.91 ▼ miss (-238.2%)

Net loss Q4 $74.1M, FY $247.3M; cash $483.8M, runway into Q4 2026 excluding revenue.
BLA for RP1+nivolumab in advanced melanoma on schedule; PDUFA July 22, 2025; no advisory committee.
Commercial infrastructure fully built and ready for launch; distribution channels established.
R&D Q4 $54.0M (+27% YoY); SG&A Q4 $25.4M (+57% YoY) driven by pre-launch scaling.
Investor day June 24; confirmatory Phase 3 IGNYTE-3 enrolling 400 patients globally.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.